Buprenorphine

点击蓝字，关注我们 编者按：阿片类药物作为中重度疼痛治疗的核心药物，在癌痛管理及慢性疼痛治疗中具有不可替代的地位。近年来，随着新型阿片药物的研发和临床应用的深入，其在镇痛效果、剂型创新、防滥用技术等方面取得了显著进展。在中国临床肿瘤学会（CSCO）肝胆胰肿瘤大会暨第十五届胰腺癌上海论坛、长三角肿瘤专科联盟年会上，中国抗癌协会理事、江苏省肿瘤医院内科主任沈波教授在主题报告中，系统梳理阿片类药物的分类、临床应用现状与新进展，以期为临床工作者提供参考。 阿片类药物综述及消耗现状 癌痛管理现状 2018年，国际权威肿瘤学期刊《临床医师癌症杂志》（CA: A Cancer Journal for Clinicians，简称CA）连续发表两篇关于癌痛管理的重要文章，分别针对医务工作者和患者，系统回顾了近40年特别是近15年来美国在癌痛管理方面的工作[1-2]。文章指出，尽管2007年至2013年间美国癌痛治疗不充分的情况下降了约25%，但仍有约1/3的癌痛患者疼痛未得到合理治疗。阻碍癌痛合理管理的主要原因包括癌痛全程管理不充分、临床医生水平有限以及患者、种族和社会经济地位差异等。针对患者，《CA》提出了专业的疼痛管理建议，包括告知患者疼痛治疗是癌症治疗的重要组成部分，鼓励患者充分向医护人员报告疼痛情况，尽早镇痛，并建议患者坚持撰写“疼痛日记”。 癌痛治疗原则 我国《癌症疼痛诊疗规范（2018年版）》明确了癌痛治疗的原则为综合治疗，主要包括病因治疗、药物治疗和非药物治疗。药物治疗是各种疼痛治疗中的主要手段，也是最基本、最常用的方法。药物治疗可达到消除或控制疼痛病因或致痛因素、维持机体内环境稳定、减轻或缓解患者痛苦、提高生活质量的目的。药物治疗需遵循五项基本原则：口服给药、按阶梯给药（三阶梯改良）、按时给药、个体化给药、注意具体细节。 近年来，癌痛治疗从三阶梯向四阶梯演进。1986年世界卫生组织（WHO）提出三阶梯给药方案，2018年《CA》更新为四阶梯治疗方案，新增了区域阻滞技术、患者自控镇痛（PCA）、神经损毁和鞘内药物输注系统等微创介入治疗[3]。 阿片类药物的作用机制 阿片类药物一直是疼痛管理的基础。我国《癌症疼痛诊疗规范（2018年版）》指出：阿片类药物是中重度疼痛治疗的首选药物[4]；欧洲肿瘤内科学会（ESMO）、日本姑息医学会（JSPM）也推荐强阿片类药物作为中重度癌痛的起始治疗药物[5-6]。目前临床常用的阿片类药物主要包括口服、注射以及经皮、经黏膜给药的剂型[7]。 阿片类药物通过多重机制抑制疼痛：在突触前水平，通过抑制Ca²⁺内流，减少P物质等疼痛神经递质的释放；在突触后水平，通过增强K⁺外流，引起神经元超极化，降低其兴奋性，从而抑制疼痛信号传递。此外，阿片类药物还可通过作用于边缘系统等高位中枢，调节疼痛情绪反应，减轻不适感。其治疗作用的核心在于抑制中枢敏化，减少脊髓水平的异常兴奋信号，阻遏病理性疼痛记忆的形成，从而打破疼痛恶性循环，实现有效镇痛[8]。 我国阿片类药物消耗情况 根据国际麻醉药品管制局（INCB）2019-2023年度报告，全球吗啡消耗量中欧洲占39.1%，美国占34.1%。中国2022年吗啡消耗量是2012年的1.8倍，十年间虽有显著增长，但在全球占比仅从2.94%增至5.60%[9]。截至2025年3月的INCB数据显示，中国阿片类药物S-DDD（统计用限定日剂量）在全球排名第115位，在亚洲排名第30位[10]。 在人均消耗量方面，INCB采用每百万居民每日统计限定日剂量（defined daily doses, DDD）作为衡量指标，若数值小于100，则被视为严重使用不足。2021—2023年间，中国人均麻醉药品消耗量排名第115位，数值仅为160。若排除主要用于成瘾治疗的美沙酮，则专门用于疼痛治疗的阿片类镇痛药物的S-DDD进一步降至129，明显低于国际水平，属于严重使用不足状态。 临床常用的阿片类药物简介 阿片类药物分类 阿片类药物可根据物质来源、化学结构、对阿片受体作用性质以及医疗用途与成瘾潜能进行分类。按作用性质可分为阿片受体激动剂（如吗啡）、部分激动剂（如丁丙诺啡）和拮抗剂（如纳洛酮）。按医疗用途可分为无医疗用途高成瘾类（如海洛因）、有医疗用途高成瘾类（如吗啡）、有医疗用途中度成瘾类（如可待因）以及成瘾度低或低滥用潜能类（如镇痛新、Buprenex）。 阿片类镇痛药的优点 临床试验表明，对非阿片类药物治疗效果不佳的患者，使用阿片类药物可以缓解疼痛。阿片类镇痛药具有多项优势：对多种疼痛、长期治疗有效；剂量无封顶效应且可调；不存在威胁生命的不可逆的靶器官毒性；在制剂成分、单剂剂量和剂型方面可选择性强。 我国《癌症疼痛诊疗规范（2018年版）》推荐常用癌痛治疗药物包括阿片生物碱及其衍生物（如吗啡、羟考酮、氢吗啡酮）、合成的阿片类药物（如芬太尼、美沙酮）以及复方制剂（如氨酚羟考酮、氨酚待因片）[4]。WHO推荐常用镇痛药物包括吗啡及其控缓释剂型、羟考酮及其控缓释剂型、芬太尼系列剂型、氢吗啡酮注射液及其缓释剂型等。 临床常用阿片类药物 1 吗啡 吗啡作为经典阿片药物，历经五代发展，从最初的不稳定形态逐步优化至稳定性最高的硫酸吗啡，其代表药物硫酸吗啡缓释片与阿片受体亲和力高，疗效增强。对于顽固性恶心、呕吐，吞咽困难或意识减退等不能口服的患者，还可通过直肠给药。 2 羟考酮 羟考酮是一种半合成蒂巴因衍生物，强阿片药物，主要与κ和μ受体结合，口服生物利用度高，与其他阿片类药物相比有明显优势。国产的盐酸羟考酮缓释片采用独特制剂工艺，从物理操作（可破坏性）、活性成分可提取性、防注射和防鼻吸等性能方面进行了升级，各性能与原研制剂相当，安全性更高，其原研制剂已成为美国唯一在售剂型。 3 氢吗啡酮 氢吗啡酮是吗啡的半合成衍生物，纯μ受体激动剂，镇痛疗效约为吗啡的5-10倍，不良反应较轻，且有改善情绪的作用。其注射剂起效快，口服缓释片作用持久，维持作用时间18~24h。 4 芬太尼 芬太尼是强效μ受体激动剂，镇痛疗效约为吗啡的100倍，脂溶性高、蛋白结合率高，生物利用度高，不良反应较吗啡轻，尤其是便秘和呼吸抑制发生率低。维持作用时间72h。是无法吞咽、恶性肠梗阻及严重肝肾衰竭患者的首选。 5 他喷他多 他喷他多是一种具有μ-阿片受体（MOR）激动和去甲肾上腺素再摄取抑制（NRI）双重作用机制的中枢镇痛药。 近年来，新型阿片药物的研发与应用不断推进。随着对阿片类药物药效学、药代动力学和药物基因组学理解的深入，其临床应用已从镇痛扩展至呼吸困难、咳嗽、难治性腹泻等症状的控制。 阿片类药物临床应用新进展 盐酸氢吗啡酮缓释片 2023年ASCO指南建议，对于即将开始阿片类药物治疗的患者，医生应提供任何经FDA或其他监管机构批准的药物，选择应基于药代动力学特征、用药途径、半衰期、神经毒性及费用等因素[11]。2018 年ESMO推荐，羟考酮和氢吗啡酮缓释片可有效替代吗啡缓释片，适用于中重度癌痛的维持治疗[12]。缓释制剂具有用药规律、减少给药次数、血药浓度稳定、延缓耐药、增加睡眠时间、减少疼痛对日常生活的影响、提高患者依从性等优点。 新一代阿片类口服长效缓释制剂盐酸氢吗啡酮缓释片，采用口服渗透泵缓释系统（OROS），药物进入胃肠道后，水分子通过半透膜进入含药层形成混悬液，助推层高分子材料吸水膨胀后产生释药动力，推动药物混悬液由激光孔缓慢释放[13-14]（图1）。 图1. 盐酸氢吗啡酮缓释片的结构及释药原理（引自讲者会议幻灯） 盐酸氢吗啡酮缓释片强效持久，口服效力是吗啡的5-10倍；单次口服后，血药浓度在用药后6-8h逐渐升高，并在约18-24h时保持稳定，其平均Tmax值约为13-16h；每日一次给药，明显减少给药次数，提高患者用药依从性[15]（图2）。 图2. 氢吗啡酮速释和缓释制剂单次给药药时曲线（引自讲者会议幻灯） 2023年国家药品审评中心（CDE）发布《阿片类口服固体仿制药防滥用药学研究技术指导原则（试行）》，与美国FDA2015年指南一致，指出防滥用技术包括物理/化学屏障、激动剂/拮抗剂组合、厌恶剂、新型给药系统等。盐酸氢吗啡酮缓释片联合使用“物理屏障”和“OROS缓释技术”两种药学技术，可有效防止滥用。 国内外氢吗啡酮缓释片临床研究对比见下表。研究显示，国产OROS氢吗啡酮缓释片在疗效和安全性方面与国外制剂产品一致，相比其他缓释制剂使用更加方便[16-17]。 表1. 国内外氢吗啡酮缓释片III期临床试验对比总结 （引自讲者会议幻灯） 表2.国内外氢吗啡酮缓释片临床研究对比 （引自讲者会议幻灯） 他喷他多片 他喷他多作为兼具μ- 阿片受体（MOR）激动与去甲肾上腺素（NE）再摄取抑制双重作用的阿片类镇痛药，其创新机制打破了传统药物的单一靶点局限[18]（图3）。其双重作用机制可多靶点协同镇痛，特别是针对复杂疼痛（如神经病理性疼痛）能够提供更全面的镇痛效果；不良反应轻，耐受性好，显著降低阿片类药物胃肠道不良反应，药物相互作用少。轻度肝损伤、轻中度肾损伤无需调整剂量，中度肝损伤低剂量降低频率给药。作为强效阿片类镇痛药，循证医学证据表明他喷他多在缓解疼痛上和羟考酮相当。 图3. 他喷他多作用机制（引自讲者会议幻灯） 他喷他多属于第三梯队强效阿片类镇痛药，被多项国内外指南与共识推荐用于中重度癌痛，尤其适用于神经病理性疼痛的单独或联合治疗[19-21]。 总结 尽管我国阿片类药物消耗量近年来有所提升，但相对于庞大的癌症发病和存活人群以及疼痛流行病学数据，癌痛管理工作仍任重道远。临床医生应深入理解疼痛的病理生理机制，掌握镇痛药物的药理学特性，根据药物作用机制合理选择药物，提倡联合用药与个体化治疗，追求最大疗效与最小不良反应。 片剂是目前临床最常用的阿片类药物剂型，不同剂型的新的阿片药物逐渐上市，为我们提供了更多的选择，应根据临床具体情况选用药物及给药途径。防滥用特性是指即使不能完全避免滥用，但也能够有效地阻止滥用。随着新型剂型和防滥用技术的不断发展，阿片类药物在临床中的应用将更加安全、有效、便捷。 参考文献：（滑动查看） 1. Scarborough BM, Smith CB. Optimal pain management for patients with cancer in  the modern era. CA Cancer J Clin. 2018 Mar 2. Pain management for patients with cancer. CA Cancer J Clin. 2018 Mar 30. doi: 10.3322/caac.21454 3. Mestdagh F, et al. Curr Oncol. 2023 Jul 18;30(7):6838-6858. 4. 中华人民共和国国家卫生健康委员会.临床肿瘤学杂志,2018,23(10):937-944. 5. Fallon M, et al. Ann Oncol. 2018 Oct 1;29(Suppl 4):iv166-iv191.  6. Clinical Guidelines from the Japanese Society of Palliative Medicine. J Palliat Med. 2022 Jul;25(7):1095-1114 7. Paice JA, et al. J Clin Oncol. 2023 Feb 1;41(4):914-930. 8. Sandkühler, J.: Pain Memory - Origin, Avoidance, and Removal. Deutsches Ärzteblatt 42, 2725-2730, 2001 9. International Narcotics Control Board (INCB) annual report（2019-2023） 10. International Narcotics Control Board (INCB) annual report（1980-2023） 11. Paice JA, Bohlke K, Barton D, et al. Use of Opioids for Adults With Pain From Cancer or Cancer Treatment: ASCO Guideline. J Clin Oncol. 2023;41(4):914-930. 12. Ann Oncol. 2018 Oct 1;29(Suppl 4):iv166-iv191. 13. Conley Robert et al.Clinical spectrum of the osmotic-controlled release oral delivery system (OROS), an advanced oral delivery form.[J] .Curr Med Res Opin, 2006, 22: 1879-92. 14. Turgeon J,Gröning R,Sathyan G et al. The pharmacokinetics of a long-acting OROS hydromorphone formulation.[J] .Expert Opin Drug Deliv, 2010, 7: 137-44. 15. Suneel,Gupta et al.Providing Constant Analgesia with OROS® Hydromorphone[J].Journal of Pain & Symptom Management, 2007. 16. J Opioid Manag. 2012 Jul­Aug;8(4):243­52 17. Pain Pract, 2013, 13(1):30-40. 18. Novel insights on the management of pain: highlights from the ‘Science of Relief’meeting 19. Centre for Clinical Practice at NICE (UK. Neuropathic pain: the pharmacological management of neuropathic pain in adults in non-specialist settings [Internet][J]. 2013. 20. Mu A, Weinberg E, Moulin D E, et al. Pharmacologic management of chronic neuropathic pain: Review of the Canadian Pain Society consensus statement[J]. Canadian Family Physician, 2017, 63(11): 844-852. 21. 周围神经病理性疼痛诊疗中国专家共识[J]. 中国疼痛医学杂志,2020,26(5):321-328. 沈波 教授 江苏省肿瘤医院/南京医科大学附属肿瘤医院  肿瘤内科主任 主任医师、研究员、博士生导师/博士后合作导师 中国抗癌协会 理事 中国临床肿瘤学会（CSCO）理事 国家卫健委能力建设和继续教育肿瘤学专委会 委员 国家肿瘤质控中心肺癌质控专家委员会 委员 中国抗癌协会肿瘤临床化疗专委会  副主委 中国抗癌协会小细胞肺癌专业委员会 副主委 中国医师协会肿瘤多学科诊疗（MDT）专委会 常委 中国医药教育协会肿瘤转移专委会 副主委 中国初级卫生保健基金会基层肿瘤防治专委会 副主委 中国临床肿瘤学会非小细胞肺癌专委会 委员 江苏省有突出贡献中青年专家 江苏省政协委员、农工党江苏省省委委员 江苏省医学会肿瘤化疗与生物治疗分会 候任主委 江苏省医师协会肿瘤多学科诊疗专委会 主委 江苏省免疫学会 副理事长/转化医学分会 主委 江苏省整合医学研究会肺癌专委会 主委 江苏省研究型医院学会罕见突变肿瘤专委会 主委 （来源：《肿瘤瞭望》编辑部） 声 明 凡署名原创的文章版权属《肿瘤瞭望》所有，欢迎分享、转载。本文仅供医疗卫生专业人士了解最新医药资讯参考使用，不代表本平台观点。该等信息不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议，如果该信息被用于资讯以外的目的，本站及作者不承担相关责任。

Award-winning journalism has drawn millions of loyal readers BOSTON, Sept. 9, 2025 /PRNewswire/ -- STAT launched 10 years ago with a mission of filling a journalistic void in coverage of health and medicine. What started then as a small operation based mostly in Boston has grown to a national brand covering scientific hubs across the United States, with a recent expansion into the U.K. and global ambitions beyond. During this time, STAT's initial lineup of nearly two dozen employees has grown to a staff of roughly 100, with outposts outside of its headquarters in Boston including New York, Washington, D.C., the Midwest, and California. Continue Reading Becoming STAT Founded by John and Linda Henry, the owners of The Boston Globe, STAT was meant to test the idea that readers would pay for high quality, in-depth news coverage of the life sciences. Under the leadership of co-founder and executive editor Rick Berke, STAT has proven that this model works, even as many other media companies have struggled and shut down. What sets STAT apart is its deep, authoritative reporting and compelling storytelling. Coverage spans both the accelerating scientific revolution and the myriad shortcomings of the U.S. health care system. We routinely publish tough-minded stories about the most influential voices and institutions in health and medicine — from drugmakers and health providers, to tech giants, scientists, and public health leaders. With these stories reaching an audience of dedicated readers, STAT has always punched above its weight. STAT's 10-year anniversary: Marking a decade of reporting from the frontiers of health and medicine Post this "We are proud that our reporting has expanded the public understanding of the worlds of health and medicine, and made a difference,'' Berke said. "One of our first achievements was successfully suing Purdue Pharma to release its secret documents on the marketing of OxyContin. We were the first U.S. news organization to seize on the novel coronavirus as a potentially catastrophic global health threat. This year, record numbers of subscribers are drawn to our deep, authoritative reporting of the upheaval we're seeing in health and medicine." Our Impact Our stories, your stories, changed the landscape of health and medicine STAT's reporting has prompted numerous investigations, led to reforms, and has expanded the public understanding of health and medicine at every level. Here are some highlights. 2019 - Secret Purdue Pharma files on its marketing of OxyContin unsealed after a nearly four-year legal fight waged by STAT. 2020 - STAT was the first U.S. news organization to seize on the novel coronavirus as a potentially catastrophic global health threat, and consistently produced vital, prescient coverage of the Covid-19 pandemic. In March 2020, the New York Times described STAT as "the medical news site that saw the coronavirus coming months ago." 2022 - Based on STAT's revelations about Biogen executives' use of a back channel to FDA officials to win approval of the Alzheimer's drug Aduhelm, a congressional investigation concludes that the approval was "rife with irregularities," including dozens of undisclosed calls and emails and an inappropriate level of coordination. 2023 - Investigation of Epic's predictive model for sepsis helps inspire first federal disclosure requirements for AI tools embedded in hospital electronic health record systems. 2023 - Medicare stepped up audits of insurers' refusal to cover patient care and issued new guidance on the use of AI tools to deny care, and two class-action lawsuits were filed in response to STAT's "Denied by AI" series, which revealed that insurers were using a computer algorithm to deny care to older and disabled patients. 2024 - STAT's yearlong "Health Care's Colossus" investigation, which documented how the conglomerate wields its market power to milk the health care system for profit, helped lead to two ongoing Justice Department investigations and spurred lawmakers' calls for reforms in the Medicare Advantage program. Readers are flocking to STAT in record numbers. They tell us they are drawn to our deep, authoritative reporting of the upheaval we're seeing in health and medicine and the reverberations for each and every one of us. We've added 45% more subscribers this summer than the previous summer, and we now have more subscribers than ever in our near 10-year history. Just in the past year, its newsroom has relentlessly covered the impact of the Trump administration on science and health care, while producing these and other groundbreaking investigative series and narrative projects: In STAT's yearlong "Coercive Care'' series, we documented the ways in which doctors have pressured women with sickle cell disease to have tubal ligations they didn't want or fully understand, as recently as 2022. "The War on Recovery'' series debunked an entrenched, defeatist narrative: that the American opioid crisis is a tragedy with no solution. The reality is that methadone and buprenorphine are highly effective in treating opioid addiction. STAT unraveled the ways in which virtually every sector of American society is obstructing the use of these medications. "Embedded Bias'' exposed the consequences of race becoming ubiquitous in medical decision-making tools. We found that race-based algorithms, often invisible to clinicians and certainly to patients, were pervasive, yet the rationale for using race was frequently unexamined or relied on weak evidence; in some cases, it traced back to erroneous slavery-era thinking. These tools have been shown to delay care and worsen health disparities. The success of all of this world-class journalism can be seen in the two Pulitzer Prize finalists and countless awards that STAT has received over the last 10 years, including the National Magazine Award for General Excellence, multiple Edward R. Murrow Awards, George W. Polk Awards, Gerald Loeb and SABEW awards, and a documentary that was nominated for an Emmy. More so, it can be seen in STAT's loyal readers who are passionate about our work. As one, Bill Herrmann, posted on social media recently, "STAT is a one-of-a-kind treasured resource, and these authors are among the best. Keep up the great work — we need it now more than ever!'' STAT's Past Decade Looking back, STAT's unique approach was evident from the start, with early investigations into IBM Watson and its exaggerated claim to revolutionize cancer care, and a nearly four-year legal battle to unseal Purdue Pharma documents shedding light on its role in the opioid crisis. STAT did not back down when such investigations built tension with its advertisers, instead relying increasingly on its subscription product, STAT+, to fuel the business. STAT also launched an opinion franchise, First Opinion, which quickly became a sought-after home for persuasive and personal essays, and would eventually include pieces written by the director-general of the World Health Organization, senators, and former directors of the CDC, among many others. STAT continued growing by pushing its journalism to new mediums. In 2018, it launched the ever-popular weekly biotech podcast "The Readout LOUD," featuring STAT's first-rate biotech reporters. Around the same time, with a growing multimedia department, STAT produced its first documentary, "Runnin'," about the toll of the opioid epidemic in Somerville, Mass. Later, STAT created a full-length documentary on the future of prosthetic limbs, "Augmented," which aired on "NOVA" in 2022 and was nominated for a national Emmy Award. Next up was the live stage, as STAT started an events business in 2019 with the goal of bringing its readers together to experience impactful live journalism, while driving revenue. It worked, and STAT's successful inaugural STAT Summit in November 2019 paved the way for an ambitious slate of events held annually across the country. After a brief pivot to all-virtual offerings during the pandemic, STAT's events program has returned with full force to in-person convenings. In addition to the flagship STAT Summit in Boston, STAT now also hosts a one-day Breakthrough Summit East in New York City and Breakthrough Summit West in San Francisco, alongside several other smaller, industry-adjacent convenings. This year's flagship summit will mark the start of STAT's 10-year anniversary, focusing on "the next 10 years" in health and medicine. When Covid hit, STAT's Helen Branswell was the first U.S.-based reporter to write about the "novel virus" in China in January 2020. While shutdowns brought plans for in-person events to a screeching halt, STAT saw traffic to its site increase nearly tenfold as millions of new readers turned to STAT as a trusted news source throughout the pandemic. During this time, STAT saw months with upward of 23 million unique visitors. Since then, this number has leveled off at closer to 3 million unique monthly visitors, but STAT's powerhouse newsroom has not slowed down. STAT continues to embrace creative storytelling tools across many platforms beyond our homepage and app, expanding our audio offerings to include the "First Opinion Podcast," and building data trackers to keep readers up to date on everything from the 150 weight loss drugs in development to the FDA's latest breakthrough device designations. In 2023, STAT released a three-part short documentary series about rural health care, and in 2024, a five-part animated explainer series on drug pricing. STAT champions its community of readers through long-standing programs like STAT Wunderkinds, which recognizes the best and brightest young minds in science each year, and STAT Madness, a bracket-style competition pitting research teams from U.S. universities against each other to find the most groundbreaking biomedical innovation of the year. A newer program, STATUS List, launched in 2022, names the leaders shaping the headlines each year, and brings them together in one room to discuss the future of health and medicine. On top of this, STAT has also built a best-in-class branded content studio, offering sophisticated and custom native advertising solutions for its clients, positioning the business for continued growth in the years ahead. Contact: Boston Globe Media Communications, 617-851-3396, [email protected] About STAT: Founded in 2015, STAT is a digital media company that focuses on delivering fast, deep, and tough-minded journalism about the life sciences. STAT takes you inside academic labs, biotech boardrooms, and political backrooms, casting a critical eye on scientific discoveries, scrutinizing corporate strategies, and chronicling the roiling battles for talent, money, and market share. With an award-winning newsroom, STAT provides indispensable insights and exclusive stories on the technologies, personalities, power brokers, and political forces driving massive changes in the life sciences industry — and a revolution in human health. About Boston Globe Media: Boston Globe Media Partners, LLC is a locally owned, award-winning media company serving Boston and New England for over 153 years. Its cornerstone is The Boston Globe, a 27-time Pulitzer Prize-winning news source and one of the most successful metro news organizations in the United States. The Globe is headquartered in Boston with regional bureaus in Washington, D.C., Rhode Island, and New Hampshire. The Globe has been successfully growing its direct subscriber base, today boasting the highest total number of subscribers the organization has had since 2008. The Globe hosts events that connect community members to its journalism and provides a range of digital and home-delivered advertising solutions that reach more consumers than any other New England media brand. Boston Globe Media's portfolio includes The Boston Globe, Globe Opinion, Boston.com, STAT, The B-Side, Globe Publishing Services, Globe Events, Studio/B, and Boston magazine. SOURCE STAT WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED